Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2
- PMID: 15531505
- DOI: 10.1210/jc.2004-1241
Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2
Abstract
Permanent neonatal diabetes mellitus (PNDM) is a rare form of diabetes characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Recently, activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 were identified in 10 PNDM patients. Tolbutamide-stimulated insulin secretion, demonstrated in 3 of these patients suggested that some PNDM patients may respond to oral sulfonylurea treatment. In this report, we describe an infant with PNDM due to an arginine-to-histidine substitution at position 201 (R201H) of the gene encoding Kir6.2. After insulin pump therapy for six months, he was shifted to oral glybenclamide therapy at a daily dose of 0.8 mg/kg. Basal c-peptide level increased by two fold during glybenclamide treatment, but no further elevation was observed following intravenous glucose administration. Outpatient, continuous glucose monitoring while on a normal infant diet demonstrated a marked improvement in glycemic control. This study demonstrates the feasibility of oral sulfonylurea treatment in PNDM patients with Kir6.2 mutations even during infancy, and the superiority of this approach over insulin administration.
Similar articles
-
Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.Arch Endocrinol Metab. 2015 Dec;59(6):559-61. doi: 10.1590/2359-3997000000076. Epub 2015 Aug 28. Arch Endocrinol Metab. 2015. PMID: 26331221
-
[Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].Lijec Vjesn. 2010 Mar-Apr;132(3-4):90-3. Lijec Vjesn. 2010. PMID: 20540435 Croatian.
-
Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.Ann Saudi Med. 2010 Mar-Apr;30(2):162-4. doi: 10.4103/0256-4947.60526. Ann Saudi Med. 2010. PMID: 20220270 Free PMC article.
-
Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.Diabetes Metab. 2006 Dec;32(6):569-80. doi: 10.1016/S1262-3636(07)70311-7. Diabetes Metab. 2006. PMID: 17296510 Review.
-
Neonatal diabetes mellitus: a disease linked to multiple mechanisms.Orphanet J Rare Dis. 2007 Mar 9;2:12. doi: 10.1186/1750-1172-2-12. Orphanet J Rare Dis. 2007. PMID: 17349054 Free PMC article. Review.
Cited by
-
Smart sensors and virtual physiology human approach as a basis of personalized therapies in diabetes mellitus.Open Biomed Eng J. 2010;4:236-49. doi: 10.2174/1874120701004010236. Epub 2010 Aug 8. Open Biomed Eng J. 2010. PMID: 21625646 Free PMC article.
-
Genetic Counseling for Diabetes Mellitus.Curr Genet Med Rep. 2014 Jun 1;2(2):56-67. doi: 10.1007/s40142-014-0039-5. Curr Genet Med Rep. 2014. PMID: 25045596 Free PMC article.
-
Transient neonatal diabetes mellitus caused by a de novoABCC8 gene mutation.Korean J Pediatr. 2011 Apr;54(4):179-82. doi: 10.3345/kjp.2011.54.4.179. Epub 2011 Apr 30. Korean J Pediatr. 2011. PMID: 21738553 Free PMC article.
-
The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet.J Physiol. 2010 Sep 1;588(Pt 17):3201-9. doi: 10.1113/jphysiol.2010.191767. Epub 2010 Jun 2. J Physiol. 2010. PMID: 20519313 Free PMC article. Review.
-
Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.Front Endocrinol (Lausanne). 2023 May 11;14:1143736. doi: 10.3389/fendo.2023.1143736. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37251668 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
